Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Medtronic
Colorcon
McKesson
Mallinckrodt

Last Updated: December 16, 2019

DrugPatentWatch Database Preview

Litigation Details for PFIZER,INC. v. SYNTHON HOLDINGS BV (M.D.N.C. 2005)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Small Molecule Drugs cited in PFIZER,INC. v. SYNTHON HOLDINGS BV
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for PFIZER,INC. v. SYNTHON HOLDINGS BV (M.D.N.C. 2005)

Date Filed Document No. Description Snippet Link To Document
2005-01-12 1 Complaint United States Patent Nos. 4,572,909 (the “’909 patent”) and 4,879,303 (the “’303 patent”). PARTIE&… United States Patent and Trademark Offlce (the “PTO”) issued to Pflzer the ’909 patent, entitled “2-(…has held title to the ’909 patent since it was issued. 14. The ’909 patent discloses and claims, in£r…extending the term of the ’909 patent for 1,252 days, until July 31, 2006 (the “Patent Terrn Restoration”). The…infringing the ’909 patent. SECOND CLAIM FOR RELIEF: INDUCING INFRINGEMENT OF THE ’909 PATENT 21. Pfizer realleges External link to document
2006-03-07 119 Memorandum and Opinion holds two patents related to its heart medication Norvasc®: the ’303 patent and U.S. Patent No. 4,572,909…amlodipine” contained within U.S. Patent No. 4,879,303 (the “’303 patent”) is “any salt that contains the…4,572,909 (“the ’909 patent”). The ’909 patent, which claims “amlodipine” and discloses as a best mode to…. The ‘909 patent is not currently at issue in this litigation.2 The ’303 patent, which is at…sought a patent on “the besylate salt of amlodipine.” The priority application for the ’303 patent was filed External link to document
2006-08-31 152 Findings of Fact and Conclusions of Law 303 Patent 84. The prior art to the ’303 patent includes (1) United States Patent No. 4,572,909 … The ’303 Patent Prosecution 73. The ’303 patent issued from the United States Patent Application… the ’909 patent. Therefore, the ’909 patent is prior art to the ’303 patent. 86…the Patent Examiner’s prior rejection of the ’303 patent for obviousness before the Patent Examiner…second patent covers matter included in the first patent, there is no double patenting problem External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Express Scripts
Merck
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.